Posted by Michael Wonder on 12 Sep 2023
Incorporating added therapeutic benefit and domestic reference pricing into Medicare payment for expensive Part B drugs
10 September 2023 - A retrospective analysis using a 20% nationally representative sample of 2015 to 2019 traditional Medicare Part B claims.
Expensive drugs were defined as having average annual spending per beneficiary exceeding the average annual social security benefit ($17,532 in 2019). For expensive drugs identified in 2019, added benefit assessments conducted by the French Haute Autorité de Santé were collected.
